Modeyso is the first and only approved treatment for recurrent H3 K27M-mutant diffuse midline glioma in patients aged one ...

Modeyso is the first drug to treat patients with diffuse midline glioma with an H3 K27M mutation, an ultra-rare and aggressive brain tumor.

Replimune Group's RP1 oncolytic virus therapy faced an FDA rejection, raising concerns about the platform's viability in ...

The FDA granted accelerated approval to dordaviprone for the treatment of patients aged 1 year and older with recurrent diffuse midline glioma who harbor the H3 K27M mutation with progressive disease ...

US FDA approves Jazz Pharmaceuticals’ Modeyso to treat recurrent H3 K27M-mutant diffuse midline glioma: Dublin Friday, August 8, 2025, 11:00 Hrs [IST] Jazz Pharmaceuticals plc, ...

Company on track to submit NDA for bitopertin in erythropoietic protoporphyria (EPP) under accelerated approval pathway in ...

The Nigeria Police Force has raised concerns over a rising trend of lobbying and unofficial promotion requests directed at ...

Avobis Bio LLC, a clinical stage company developing implantable cell therapies, announced today that primary analysis of the ...

The FDA has granted accelerated approval to dordaviprone for the treatment of diffuse midline glioma with an H3 K27M mutation in patients one year old and older with progressive disease following ...

The Nigeria Police Force said it has observed with concern the growing wave of lobbying and unofficial requests to ...

Discover groundbreaking research from Harvard Medical School revealing lithium's critical role in brain health, aging and ...

Expansion of illegal Israeli settlements has rapidly accelerated under the far-right Netanyahu government, which has overseen ...